Pipeline
Advancing novel precision therapeutics for serious cardiovascular diseases
Cardiovascular
Program
Indications
| Preclinical | Phase 1 | Phase 2 | Pivotal / Phase 3 |
Regulatory Submission |
EDG-7500 is an investigational, novel oral, selective, cardiac sarcomere modulator for the treatment of symptomatic HCM.
EDG-15400 is an investigational, novel oral, selective, cardiac sarcomere modulator, for the treatment of HFpEF.
EDG-7500, EDG-15400 and EDG-003 are investigational therapies that have not been approved for use in HCM or HF by any regulatory agency, as their safety and effectiveness have not been established for the treatment of these diseases.
Is a clinical trial right for you?
We are currently conducting clinical trials in severe cardiovascular diseases.
